vs
Pacira BioSciences, Inc.（PCRX）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是REPUBLIC BANCORP INC的1.9倍（$177.4M vs $94.3M），REPUBLIC BANCORP INC净利率更高（24.2% vs 1.6%，领先22.6%），REPUBLIC BANCORP INC同比增速更快（5.3% vs 5.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -11.5%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
PCRX vs RBCAA — 直观对比
营收规模更大
PCRX
是对方的1.9倍
$94.3M
营收增速更快
RBCAA
高出0.3%
5.0%
净利率更高
RBCAA
高出22.6%
1.6%
两年增速更快
PCRX
近两年复合增速
-11.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $94.3M |
| 净利润 | $2.9M | $22.8M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | 29.3% |
| 净利率 | 1.6% | 24.2% |
| 营收同比 | 5.0% | 5.3% |
| 净利润同比 | — | 20.0% |
| 每股收益（稀释后） | $0.07 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRBCAA
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $94.3M | ||
| Q3 25 | $179.5M | $93.5M | ||
| Q2 25 | $181.1M | $93.8M | ||
| Q1 25 | $168.9M | $135.8M | ||
| Q4 24 | $187.3M | $89.5M | ||
| Q3 24 | $168.6M | $88.1M | ||
| Q2 24 | $178.0M | $86.9M |
净利润PCRXRBCAA
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $22.8M | ||
| Q3 25 | $5.4M | $29.7M | ||
| Q2 25 | $-4.8M | $31.5M | ||
| Q1 25 | $4.8M | $47.3M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $-143.5M | $26.5M | ||
| Q2 24 | $18.9M | $25.2M |
毛利率PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXRBCAA
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 29.3% | ||
| Q3 25 | 3.5% | 40.4% | ||
| Q2 25 | 4.7% | 43.0% | ||
| Q1 25 | 1.2% | 44.1% | ||
| Q4 24 | 13.2% | 25.8% | ||
| Q3 24 | -82.8% | 38.4% | ||
| Q2 24 | 15.9% | 37.0% |
净利率PCRXRBCAA
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 24.2% | ||
| Q3 25 | 3.0% | 31.8% | ||
| Q2 25 | -2.7% | 33.5% | ||
| Q1 25 | 2.8% | 34.8% | ||
| Q4 24 | — | 21.2% | ||
| Q3 24 | -85.1% | 30.1% | ||
| Q2 24 | 10.6% | 29.0% |
每股收益（稀释后）PCRXRBCAA
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $1.1B |
| 总资产 | $1.2B | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRBCAA
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $220.0M | ||
| Q3 25 | $246.3M | $484.2M | ||
| Q2 25 | $445.9M | $484.8M | ||
| Q1 25 | $493.6M | $793.0M | ||
| Q4 24 | $484.6M | $432.2M | ||
| Q3 24 | $453.8M | $530.9M | ||
| Q2 24 | $404.2M | $400.1M |
总债务PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXRBCAA
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $1.1B | ||
| Q3 25 | $727.2M | $1.1B | ||
| Q2 25 | $757.8M | $1.1B | ||
| Q1 25 | $798.5M | $1.0B | ||
| Q4 24 | $778.3M | $992.0M | ||
| Q3 24 | $749.6M | $979.7M | ||
| Q2 24 | $879.3M | $955.4M |
总资产PCRXRBCAA
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $7.0B | ||
| Q3 25 | $1.3B | $7.0B | ||
| Q2 25 | $1.5B | $7.0B | ||
| Q1 25 | $1.6B | $7.1B | ||
| Q4 24 | $1.6B | $6.8B | ||
| Q3 24 | $1.5B | $6.7B | ||
| Q2 24 | $1.6B | $6.6B |
负债/权益比PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $168.2M |
| 自由现金流经营现金流 - 资本支出 | — | $161.1M |
| 自由现金流率自由现金流/营收 | — | 170.9% |
| 资本支出强度资本支出/营收 | — | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | — | $288.6M |
8季度趋势，按日历期对齐
经营现金流PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $168.2M | ||
| Q3 25 | $60.8M | $33.3M | ||
| Q2 25 | $12.0M | $8.4M | ||
| Q1 25 | $35.5M | $93.2M | ||
| Q4 24 | $33.1M | $149.0M | ||
| Q3 24 | $53.9M | $51.3M | ||
| Q2 24 | $53.2M | $4.0M |
自由现金流PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $161.1M | ||
| Q3 25 | $57.0M | $30.8M | ||
| Q2 25 | $9.3M | $5.2M | ||
| Q1 25 | $26.9M | $91.6M | ||
| Q4 24 | $31.0M | $143.2M | ||
| Q3 24 | $49.8M | $49.8M | ||
| Q2 24 | $51.6M | $2.7M |
自由现金流率PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 170.9% | ||
| Q3 25 | 31.7% | 32.9% | ||
| Q2 25 | 5.1% | 5.5% | ||
| Q1 25 | 15.9% | 67.4% | ||
| Q4 24 | 16.6% | 160.0% | ||
| Q3 24 | 29.6% | 56.5% | ||
| Q2 24 | 29.0% | 3.1% |
资本支出强度PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 7.5% | ||
| Q3 25 | 2.2% | 2.6% | ||
| Q2 25 | 1.5% | 3.5% | ||
| Q1 25 | 5.1% | 1.2% | ||
| Q4 24 | 1.1% | 6.5% | ||
| Q3 24 | 2.4% | 1.7% | ||
| Q2 24 | 0.9% | 1.5% |
现金转化率PCRXRBCAA
| Q1 26 | — | — | ||
| Q4 25 | — | 7.37× | ||
| Q3 25 | 11.20× | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | 7.37× | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | 2.82× | 0.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RBCAA
暂无分部数据
